NCT07733180

A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-08-31Est. Completion: 2028-02-28

Enrollment target: 30 participants

Contact

Study Directorclinicaltrials@beonemed.com 1-877-828-5568

Other microbiome trials you might be interested in

Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCPhase 2Recruiting

Esophageal Cancer

A total of 120 patients with unresectable, locally advanced esophageal squamous cell carcinoma patients will be enrolled…

Beijing, ChinaEst. completion Dec 31, 2027

View Trial →

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsPhase 1Recruiting

Advanced/Metastatic Solid TumorsColorectal CancerGastric CancerGastroesophageal-junction CancerNSCLCHNSCCHead and Neck Squamous Cell CarcinomaEsophageal Cancer

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.